N/A N=26 Diagnostic

Respiratory Impedance and Obliterative Bronchiolitis

Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis

Bottom Line

View on ClinicalTrials.gov: NCT01255449 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2013

Primary outcome: Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: albuterol (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Primary completion: Mar 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	0.07	—
SECONDARY Post-HSCT Changes in Lung Tissue Density	0.03	—

Summary

The aim of the present study will be to test the hypothesis that changes in within-breath total respiratory input impedance (Zrs) may provide an early evidence of obliterative bronchiolitis after allogeneic hematopoietic stem cell transplantation (HSCT). Before and after HSCT, Zrs will be measured by a modified forced oscillation technique (FOT) during spontaneous breathing both at baseline and 30 min after albuterol inhalation . Such technique may be particularly sensitive to small changes in lung mechanics observed in the early stages of peripheral airflow obstruction.

Eligibility Criteria

Inclusion Criteria

consecutive, clinically-stable, outpatients undergoing allogeneic HSCT (sourcing from bone marrow) for hematological malignancies
values of standard PFTs within normal range before HSCT
good collaboration during the maneuvers

Exclusion Criteria

patients showing any spirometric and/or volumetric abnormality before HSCT
poor collaboration and/or coordination during the maneuvers
any clinically-significant respiratory disease (bronchial asthma, COPD, cystic fibrosis, etc.) before HSCT

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01255449). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.